Belatacept

From Wikipedia, the free encyclopedia

You have new messages (last change).

Belatacept is a hybrid protein composed of an immunoglobulin, and CTLA 4, which is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell activation. It was developed by Bristol-Myers-Squibb.

It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors.


Immunosuppressants (L04) edit

Abetimus, Adalimumab, Afelimomab , Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit) , Azathioprine, Basiliximab, Ciclosporin, Daclizumab, Efalizumab, Etanercept, Everolimus, Gusperimus , Infliximab, Leflunomide, Methotrexate , Muromonab-CD3 , Mycophenolic acid, Natalizumab, Pimecrolimus, Tacrolimus, Thalidomide, Sirolimus
Retrieved from "http://en.wikipedia.org../../../b/e/l/Belatacept.html"